August 14, 2024
Press Releases
February 1, 2024
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
November 21, 2023
International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma
October 5, 2023
Panavance to Present at the BIO Investor Forum
September 12, 2023
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
July 5, 2023
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
June 29, 2023
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)
May 24, 2023
Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention
April 17, 2023
Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
April 12, 2023